The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.